Fresenius Medical Care (NYSE:FMS) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Fresenius Medical Care (NYSE:FMS) from a hold rating to a strong-buy rating in a report released on Wednesday.

Several other research firms have also issued reports on FMS. Truist Financial raised their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Price Performance

NYSE:FMS opened at $24.54 on Wednesday. The firm has a market capitalization of $14.40 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 0.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The business has a 50 day simple moving average of $23.29 and a 200-day simple moving average of $21.30. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $25.25.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The company had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.36 billion. During the same period last year, the company earned $0.31 earnings per share. Equities analysts forecast that Fresenius Medical Care will post 1.53 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its position in Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the period. Allworth Financial LP raised its stake in shares of Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after acquiring an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care during the third quarter valued at approximately $38,000. GAMMA Investing LLC boosted its holdings in shares of Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares during the period. Finally, ORG Wealth Partners LLC bought a new position in Fresenius Medical Care in the third quarter worth approximately $112,000. 8.37% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.